Abstract：Objective: To study the changes of the proportion of myeloidderived suppressor cells(MDSCs) in the peripheral blood of patients with lung cancer, and to analyze its relationship with T lymphocyte subsets, and its clinical significance. Methods: A total of 20 healthy people and 30 lung cancer patients were selected and their peripheral blood samples were also collected. In addition, 15 lung cancer patients who were 30 days after operation were selected and their peripheral blood samples were also collected. The proportion of HLADR-CD33+ CD11+MDSCs and the proportion of T lymphocyte subsets in peripheral blood were detected by flow cytometry. The proportion of MDSCs and their correlation with T lymphocyte subsets were analyzed. Results: Compared with healthy controls, the proportion of HLADRˉCD33+CD11+ MDSCs in peripheral blood of patients with lung cancer was significantly increased (P<0.05). The proportion of CD3+T cells, CD4+T cells and CD4+/CD8+ in lung cancer patients were significantly lower than those in healthy controls (P<0.05), while the proportion of CD8+T cells was higher than healthy controls(P<0.05). The level of MDSCs in peripheral blood of patients with lung cancer after operation was lower than that before operation (P<0.05). The proportion of MDSCs in peripheral blood of patients with lymph node metastasis was significantly higher than that without lymph node metastasis (P<0.05). The peripheral blood of patients with lung cancer at stage Ⅲ-Ⅳ was higher than that at stage Ⅰ-Ⅱ(P<0.05). The proportion of MDSCs in peripheral blood of patients with lung cancer was negatively correlated with the proportion of CD4+ T cells(r=-0.524 4,P<0.01), and positively correlated with the proportion of CD8+ T cells(r=0.444 9,P<0.05). Conclusion: The proportion of MDSCs in peripheral blood of patients with lung cancer was increased and correlated with the number of T lymphocyte subsets, which might exert immunosuppressive effect on the organisms.
通讯作者:
王胜军(通讯作者)：教授，博士生导师，E-mail:sjwsj@ujs.edu.cn
作者简介: 彭蓉蓉(1983—)，女，江苏溧阳人，主管检验师，主要从事医学检验工作
引用本文:
彭蓉蓉1，2， 王胜军1. 肺癌患者外周血中髓源性抑制细胞的比例及其意义[J]. 江苏大学学报:医学版, 2019, 29(01): 54-57.
PENG Rong-rong1,2, WANG Sheng-jun1. Proportion of myeloidderived suppressor cells in peripheral blood
of patients with lung cancer and its significance
. Journal of Jiangsu University(Medicine Edition), 2019, 29(01): 54-57.
［1］She J, Yang P, Hong Q, et al. Lung cancer in China: challenges and interventions\[J\]. Chest, 2013,143(4):1117-1126.［2］Kumar V, Patel S, Tcyganov E, et al. The nature of myeloidderived suppressor cells in the tumor microenvironment\[J\]. Trends Immunol, 2016 , 37(3): 208-220.［3］Lin Y, Yang X, Liu W, et al. Chemerin has a protective role in hepatocellular carcinoma by inhibiting the expression of IL6 and GMCSF and MDSC accumulation\[J\]. Oncogene, 2017, 36(25): 3599-3608.［4］Marx J. Cancer′s bulwark against immune attack: MDS cells \[J\]. Science, 2008, 319(5860): 154-156.［5］张瑞萍，徐冰心，王社论，等.恶性肿瘤患者外周血调节性T细胞及TH1,TH2细胞的检测和临床意义\[J\].中国临床医学，2012，19(6)：602-604.［6］吴志丹,王珂,林江, 等. 胃癌患者外周血中髓源性抑制细胞的表达与机体免疫功能关系的分析\[J\]. 世界最新医学信息文摘，2018，18(64)：6-7.［7］Chen Y, Pan G, Tian D, et al. Functional analysis of CD14+HLADR-/low myeloidderived suppressor cells in patients with lung squamous cell carcinoma\[J\].Oncol Lett, 2017, 14(1): 349-354.［8］Sinha P, Okoro C, Foell D, et al. Proinflammatory s100 proteins regulate the accumulation of myeloidderived suppressor cells\[J\]. J Immunol, 2008, 181(7): 4666-4675.［9］DiazMontero CM, Salem ML, Nishimura MI, et al. Increased circulating myeloidderived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicincyclophosphamide chemotherapy\[J\]. Cancer Immunol Immunother, 2009, 58(1):49-59.
2019, Vol. 29 
